36 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
20
Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
Hoffmann-La Roche
16
Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual actinga4ß1 anda4ß7 receptor antagonists.
Hoffmann-La Roche
3
Synthesis and biological evaluation of tyrosine modified analogues of thea4ß7 integrin inhibitor biotin-R8ERY.
University of Auckland
1
Tyrosine modified analogues of thea4ß7 integrin inhibitor biotin-R8ERY prepared via Click Chemistry: synthesis and biological evaluation.
University of Auckland
14
Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.
Millennium Pharmaceuticals
30
Synthesis and SAR of pyridazinone-substituted phenylalanine amide alpha4 integrin antagonists.
Johnson & Johnson Pharmaceutical Research & Development
37
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.
Genentech
8
Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
Merck Research Laboratories
21
Amidines as amide bond replacements in VLA-4 antagonists.
Merck Research Laboratories
65
N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.
Merck Research Laboratories
17
Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.
Genentech
22
N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
Merck Research Laboratories
39
Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
Merck Research Laboratories
46
Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
Merck Research Laboratories
25
The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Merck Research Laboratories
12
Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.
Merck Research Laboratories
22
Design and synthesis of potent and selective inhibitors of integrin VLA-4.
Novartis Institute For Biomedical Research
53
The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.
Merck Research Laboratories
6
Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists.
Technische UniversitäT MüNchen
16
Cell adhesion antagonists: synthesis and evaluation of a novel series of phenylalanine based inhibitors.
Millennium Pharmaceutical
15
Discovery and evaluation of potent, tyrosine-based alpha4beta1 integrin antagonists.
Celltech Chiroscience
13
Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
Biogen
7
Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay.
University of Bologna
21
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
University of Bradford
557
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Array Biopharma
198
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
Sk Biopharmaceuticals
14
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof
Shenyang Sunshine Pharmaceutical
13
[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Abbott Laboratories